{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:22:29Z","timestamp":1707524549315},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,21]]},"DOI":"10.7759\/cureus.21481","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T21:02:37Z","timestamp":1642798957000},"source":"Crossref","is-referenced-by-count":0,"title":["A Late Diagnosis of Transthyretin Amyloidosis"],"prefix":"10.7759","author":[{"given":"Kristopher S","family":"Pfirman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Newton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collins","family":"Garst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharvil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Dawson Dowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crvasa.2012.11.018","article-title":"Cardiac amyloidosis: a comprehensive review","volume":"55","author":"Fikrle M","year":"2013","unstructured":"Fikrle M, Pale\u010dek T, Kuchynka P, N\u011bme\u010dek E, Bauerov\u00e1 L, Straub J, Ry\u0161av\u00e1 R. Cardiac amyloidosis: a comprehensive review. Cor Vasa. 2013, 55:e60-e75. 10.1016\/j.crvasa.2012.11.018","journal-title":"Cor Vasa"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.069195","article-title":"Cardiac amyloidosis","volume":"126","author":"Quarta CC","year":"2012","unstructured":"Quarta CC, Kruger JL, Falk RH. Cardiac amyloidosis. Circulation. 2012, 126:e178-82. 10.1161\/CIRCULATIONAHA.111.069195","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg FL","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019, 73:2872-91.","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/EHF2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment","volume":"6","author":"Yamamoto H","year":"2019","unstructured":"Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019, 6:1128-39. 10.1002\/EHF2.12518","journal-title":"ESC Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/CLC.23434","article-title":"Diagnosis and treatment of transthyretin-related amyloidosis cardiomyopathy","volume":"43","author":"Teng C","year":"2020","unstructured":"Teng C, Li P, Bae JY, Pan S, Dixon RAF, Liu Q. Diagnosis and treatment of transthyretin-related amyloidosis cardiomyopathy. Clin Cardiol. 2020, 43:1223-1231. 10.1002\/CLC.23434","journal-title":"Clin Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer MS","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, et al.. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019, 12:e006075. 10.1161\/CIRCHEARTFAILURE.119.006075","journal-title":"Circ Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore JD","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al.. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016, 133:2404-12. 10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/EURHEARTJ\/EHZ905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko L","year":"2020","unstructured":"Chacko L, Martone R, Bandera F, et al.. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J. 2020, 41:1439-47. 10.1093\/EURHEARTJ\/EHZ905","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016.2.2.115","article-title":"The role of cardiovascular magnetic resonance imaging in heart failure","volume":"2","author":"Peterzan MA","year":"2016","unstructured":"Peterzan MA, Rider OJ, Anderson LJ. The role of cardiovascular magnetic resonance imaging in heart failure. Card Fail Rev. 2016, 2:115-22. 10.15420\/cfr.2016.2.2.115","journal-title":"Card Fail Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.10051","article-title":"Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement","volume":"47","author":"Kellman P","year":"2002","unstructured":"Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med. 2002, 47:372-83. 10.1002\/mrm.10051","journal-title":"Magn Reson Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-018-0478-3","article-title":"Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis","volume":"20","author":"Ridouani F","year":"2018","unstructured":"Ridouani F, Damy T, Tacher V, et al.. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson. 2018, 20:58. 10.1186\/s12968-018-0478-3","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana M","year":"2014","unstructured":"Fontana M, Banypersad SM, Treibel TA, et al.. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014, 7:157-65. 10.1016\/j.jcmg.2013.10.008","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.112.978627","article-title":"Quantification of myocardial extracellular volume fraction in systemic al amyloidosis","volume":"6","author":"Banypersad SM","year":"2013","unstructured":"Banypersad SM, Sado DM, Flett AS, et al.. Quantification of myocardial extracellular volume fraction in systemic al amyloidosis. Circ Cardiovasc Imaging. 2013, 6:34-9. 10.1161\/CIRCIMAGING.112.978627","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-016-0308-4","article-title":"Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review","volume":"18","author":"Haaf P","year":"2017","unstructured":"Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2017, 18:89. 10.1186\/s12968-016-0308-4","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.626414","article-title":"Cardiac magnetic resonance predicting outcomes among patients at risk for cardiac AL amyloidosis","volume":"8","author":"Agha AM","year":"2021","unstructured":"Agha AM, Palaskas N, Patel AR, et al.. Cardiac magnetic resonance predicting outcomes among patients at risk for cardiac AL amyloidosis. Front Cardiovasc Med. 2021, 8:626414. 10.3389\/fcvm.2021.626414","journal-title":"Front Cardiovasc Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/EURHEARTJ\/EHZ298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin M","year":"2019","unstructured":"Emdin M, Aimo A, Rapezzi C, et al.. Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J. 2019, 40:3699-706. 10.1093\/EURHEARTJ\/EHZ298","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10143-4","article-title":"The use of diflunisal for transthyretin cardiac amyloidosis: a review","volume":"16","author":"Ibrahim M","year":"2021","unstructured":"Ibrahim M, Saint Croix GR, Lacy S, et al.. The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Fail Rev. 2021, 16:10.1007\/s10741-021-10143-4","journal-title":"Heart Fail Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/JAMACARDIO.2019.0849","article-title":"Association of Patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis. The APOLLO Study","volume":"4","author":"Minamisawa M","year":"2019","unstructured":"Minamisawa M, Claggett B, Adams D, et al.. Association of Patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis. The APOLLO Study. JAMA Cardiol. 2019, 4:466-72. 10.1001\/JAMACARDIO.2019.0849","journal-title":"JAMA Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi C","year":"2021","unstructured":"Rapezzi C, Elliott P, Damy T, et al.. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Heart Fail. 2021, 9:115-23. 10.1016\/j.jchf.2020.09.011","journal-title":"JACC Heart Fail"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Casta\u00f1o A","year":"2012","unstructured":"Casta\u00f1o A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012, 18:315-9. 10.1111\/j.1751-7133.2012.00303.x","journal-title":"Congest Heart Fail"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-10-S1-O23","article-title":"Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study","volume":"10","author":"Quarta CC","year":"2015","unstructured":"Quarta CC, Ozer S, Whelan CJ, et al.. Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study. Orphanet J Rare Dis. 2015, 10:O23. 10.1186\/1750-1172-10-S1-O23","journal-title":"Orphanet J Rare Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann G","year":"2020","unstructured":"Lohrmann G, Pipilas A, Mussinelli R, et al.. Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Card Fail. 2020, 26:753-9. 10.1016\/j.cardfail.2019.11.024","journal-title":"J Card Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/78110-a-late-diagnosis-of-transthyretin-amyloidosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:19Z","timestamp":1707507799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/78110-a-late-diagnosis-of-transthyretin-amyloidosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.21481","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}